NASDAQ:TRVN Trevena (TRVN) Stock Price, News & Analysis → These AI trades triggered this morning (545% return) (From Prosper Trading Academy) (Ad) Free TRVN Stock Alerts $0.41 0.00 (-0.39%) (As of 10:46 AM ET) Add Compare Share Share Today's Range$0.38▼$0.4150-Day Range$0.35▼$0.5952-Week Range$0.30▼$3.28Volume10,876 shsAverage Volume178,780 shsMarket Capitalization$7.46 millionP/E RatioN/ADividend YieldN/APrice Target$9.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Trevena alerts: Email Address Trevena MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,100.5% Upside$9.00 Price TargetShort InterestHealthy0.33% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.44Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.28) to ($0.98) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.54 out of 5 stars 3.5 Analyst's Opinion Consensus RatingTrevena has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageTrevena has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.33% of the float of Trevena has been sold short.Short Interest Ratio / Days to CoverTrevena has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Trevena has recently decreased by 47.78%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTrevena does not currently pay a dividend.Dividend GrowthTrevena does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TRVN. Previous Next 2.5 News and Social Media Coverage News SentimentTrevena has a news sentiment score of 0.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Trevena this week, compared to 1 article on an average week.Search Interest4 people have searched for TRVN on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Trevena insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.40% of the stock of Trevena is held by insiders.Percentage Held by InstitutionsOnly 13.56% of the stock of Trevena is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Trevena are expected to grow in the coming year, from ($1.28) to ($0.98) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Trevena is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Trevena is -0.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About Trevena Stock (NASDAQ:TRVN)Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is based in Chesterbrook, Pennsylvania.Read More TRVN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart TRVN Stock News HeadlinesApril 22, 2024 | americanbankingnews.comTrevena (NASDAQ:TRVN) Coverage Initiated by Analysts at StockNews.comApril 21, 2024 | msn.comTrevena Cross free art exhibition featuring local artistsApril 26, 2024 | Behind the Markets (Ad)The World's First "$20 Trillion Drug?"One small biotech holds the key to a revolution in treating Alzheimer's disease. Jeff Bezos, Goldman Sachs & Big Pharma giants have invested billions into this unknown biotech. Our research proves that anyone who gets in today could see gains as high as 113,000%!April 18, 2024 | msn.comTrevena (TRVN) Price Target Decreased by 7.69% to 6.12April 5, 2024 | morningstar.comTrevena Inc TRVNApril 4, 2024 | msn.comDanny Huston, Graham Greene, Martin Sensmeier, Oliver Trevena & Devaughn Nixon Join Joel Kinnaman Thriller ‘Ice Fall', Filming Underway In BulgariaApril 3, 2024 | msn.comTrevena Ramps Up Efforts on TRV045, Turns Attention Away from OLINVYK Amid Challenging Hospital EnvironmentApril 2, 2024 | benzinga.comRecap: Trevena Q4 EarningsApril 26, 2024 | Crypto Swap Profits (Ad)Claim Your Complimentary Bitcoin RewardMany have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.April 1, 2024 | globenewswire.comTrevena Reports Fourth Quarter 2023 Results and Provides Corporate UpdateMarch 16, 2024 | msn.comTrevena Cross cafe reopening as the Palm Tree BistroMarch 8, 2024 | msn.comThe Palm Tree Bistro at Trevena Cross Nurseries reopeningFebruary 22, 2024 | benzinga.comTrevena Stock (NASDAQ:TRVN), Short Interest ReportJanuary 10, 2024 | msn.comTrevena files to sell 2.78M shares for holdersDecember 28, 2023 | finance.yahoo.comTrevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant ExerciseDecember 28, 2023 | finance.yahoo.comTrevena Announces the Closing of $4 Million Concurrent Private Placement and Warrant ExerciseDecember 27, 2023 | msn.comTrevena announces private placement and warrant exerciseDecember 27, 2023 | markets.businessinsider.comTrevena Inc. Announces $4 Million Concurrent Private Placement and Warrant ExerciseDecember 27, 2023 | finance.yahoo.comTrevena Inc. Announces $4 Million Concurrent Private Placement and Warrant ExerciseDecember 16, 2023 | msn.comFrank Grillo Joins Olga Kurylenko & Oliver Trevena In Home Invasion Thriller ‘Misdirection’December 15, 2023 | msn.comFrank Grillo Joins Olga Kurylenko & Oliver Trevena In Home Invasion Thriller ‘Misdirection'December 4, 2023 | finance.yahoo.comTrevena Awarded OLINVYK Agreement with Premier, Inc.December 4, 2023 | finance.yahoo.comTrevena Announces TRV045 Presentation at the American College of Neuropsychopharmacology 62nd Annual MeetingNovember 30, 2023 | finance.yahoo.comTrevena Announces Acceptance of Abstract Examining the Use of OLINVYK in Patients with Acute Burn InjuriesNovember 17, 2023 | finance.yahoo.comTrevena Third Quarter 2023 Earnings: Revenues Beat Expectations, EPS LagsNovember 15, 2023 | finance.yahoo.comTrevena, Inc. (NASDAQ:TRVN) Q3 2023 Earnings Call TranscriptNovember 14, 2023 | finanznachrichten.deTrevena, Inc.: Trevena Reports Third Quarter 2023 Results and Provides Business UpdateSee More Headlines Receive TRVN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trevena and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/01/2024Today4/26/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:TRVN CUSIPN/A CIK1429560 Webwww.trevena.com Phone(610) 354-8840FaxN/AEmployees23Year FoundedN/APrice Target and Rating Average Stock Price Target$9.00 High Stock Price Target$9.00 Low Stock Price Target$9.00 Potential Upside/Downside+2,100.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($3.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,290,000.00 Net MarginsN/A Pretax Margin-1,289.25% Return on Equity-1,018.15% Return on Assets-98.93% Debt Debt-to-Equity Ratio8.35 Current Ratio4.66 Quick Ratio4.66 Sales & Book Value Annual Sales$3.12 million Price / Sales2.40 Cash FlowN/A Price / Cash FlowN/A Book Value($0.44) per share Price / Book-0.93Miscellaneous Outstanding Shares18,320,000Free Float17,881,000Market Cap$7.49 million OptionableOptionable Beta1.10 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesMs. Carrie L. Bourdow (Age 61)President, CEO & Chairman Comp: $1MMr. Barry Shin (Age 52)Executive VP, COO & CFO Comp: $670.02kDr. Mark A. Demitrack M.D. (Age 66)Senior VP & Chief Medical Officer Comp: $690.32kDr. Howard A. Rockman M.D.Scientific Founder, Consultant and Member of Scientific Advisory BoardMr. Joel SolomonVP, General Counsel & Chief Compliance OfficerMr. Michael CatalanoVice President of MarketingMr. Robert T. Yoder (Age 58)Senior VP, Chief Business Officer & Head of Commercial Operations Comp: $490.64kMs. Patricia M. Drake (Age 58)Senior VP & Chief Commercial Officer More ExecutivesKey CompetitorsCan-Fite BioPharmaNYSE:CANFClever LeavesNASDAQ:CLVReFFECTOR TherapeuticsNASDAQ:EFTRGraybug VisionNASDAQ:GRAYProtagenic TherapeuticsNASDAQ:PTIXView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 797,714 shares on 2/13/2024Ownership: 4.614%View All Institutional Transactions TRVN Stock Analysis - Frequently Asked Questions Should I buy or sell Trevena stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Trevena in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" TRVN shares. View TRVN analyst ratings or view top-rated stocks. What is Trevena's stock price target for 2024? 1 analysts have issued 1-year price objectives for Trevena's shares. Their TRVN share price targets range from $9.00 to $9.00. On average, they predict the company's stock price to reach $9.00 in the next year. This suggests a possible upside of 2,100.5% from the stock's current price. View analysts price targets for TRVN or view top-rated stocks among Wall Street analysts. How have TRVN shares performed in 2024? Trevena's stock was trading at $0.7221 at the beginning of 2024. Since then, TRVN shares have decreased by 43.4% and is now trading at $0.4090. View the best growth stocks for 2024 here. Are investors shorting Trevena? Trevena saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 58,900 shares, a drop of 47.8% from the March 31st total of 112,800 shares. Based on an average daily trading volume, of 203,300 shares, the days-to-cover ratio is presently 0.3 days. Currently, 0.3% of the company's stock are short sold. View Trevena's Short Interest. When is Trevena's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our TRVN earnings forecast. How were Trevena's earnings last quarter? Trevena, Inc. (NASDAQ:TRVN) posted its quarterly earnings results on Monday, April, 1st. The biopharmaceutical company reported ($1.06) EPS for the quarter. The biopharmaceutical company earned ($0.08) million during the quarter, compared to analyst estimates of $0.09 million. When did Trevena's stock split? Trevena's stock reverse split on Wednesday, November 9th 2022. The 1-25 reverse split was announced on Wednesday, November 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, November 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Trevena own? Based on aggregate information from My MarketBeat watchlists, some companies that other Trevena investors own include Conatus Pharmaceuticals (CNAT), Novavax (NVAX), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), Bionano Genomics (BNGO) and Dynavax Technologies (DVAX). How do I buy shares of Trevena? Shares of TRVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:TRVN) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve GoldRich Dad Poor Dad Author Shocks Millions With 2024 Crash WarningAmerican Hartford Gold Group Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trevena, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
